The total return over the past 12 months is -20.35% vs. +16.94% for the S&P 500. So far it's up +1.67% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (20.35%) | (30.98%) | N/A | N/A | N/A | N/A |
| Total Return CAGR | (20.35%) | (30.98%) | N/A | N/A | N/A | N/A |
| Revenue CAGR | +327.25% | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Xilio Therapeutics, Inc. (XLO)
| Year | Start price | End price | XLO Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $8.96 | $9.11 | +1.67% | +14.51% | (12.84%) |
| 2025 | $13.37 | $8.96 | (32.98%) | +17.72% | (50.70%) |
| 2024 | $7.70 | $13.37 | +73.64% | +24.89% | +48.75% |
| 2023 | $37.66 | $7.70 | (79.55%) | +26.19% | (105.74%) |
| 2022 | $224.00 | $37.66 | (83.19%) | (18.17%) | (65.02%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
